Interleukin-15 enhances the proliferation, stimulatory phenotype, and antitumor effector functions of human gamma delta T cells by Heleen H. Van Acker et al.
RESEARCH Open Access
Interleukin-15 enhances the proliferation,
stimulatory phenotype, and antitumor
effector functions of human gamma delta T
cells
Heleen H. Van Acker1*, Sébastien Anguille1,2, Yannick Willemen1, Johan M. Van den Bergh1, Zwi N. Berneman1,2,
Eva Lion1,2, Evelien L. Smits1,2,3† and Viggo F. Van Tendeloo1†
Abstract
Background: Adoptive immunotherapy is gaining momentum to fight malignancies, whereby γδ T cells have
received recent attention as an alternative cell source as to natural killer cells and αβ T cells. The advent of γδ T
cells is largely due to their ability to recognize and target tumor cells using both innate characteristic and T cell
receptor (TCR)-mediated mechanisms, their capacity to enhance the generation of antigen-specific T cell responses,
and their potential to be used in an autologous or allogeneic setting.
Methods: In this study, we explored the beneficial effect of the immunostimulatory cytokine interleukin (IL)-15 on
purified γδ T cells and its use as a stimulatory signal in the ex vivo expansion of γδ T cells for adoptive transfer. The
expansion protocol was validated both with immune cells of healthy individuals and acute myeloid leukemia
patients.
Results: We report that the addition of IL-15 to γδ T cell cultures results in a more activated phenotype, a higher
proliferative capacity, a more pronounced T helper 1 polarization, and an increased cytotoxic capacity of γδ T cells.
Moreover γδ T cell expansion starting with peripheral blood mononuclear cells from healthy individuals and acute
myeloid leukemia patients is boosted in the presence of IL-15, whereby the antitumor properties of the γδ T cells
are strengthened as well.
Conclusions: Our results support the rationale to explore the use of IL-15 in clinical adoptive therapy protocols
exploiting γδ T cells.
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Background
Cellular immunotherapy for cancer is a rapidly evolving
field, endeavoring to deal with common relapse or resist-
ance to conventional treatments. Herewith, most inter-
esting are the γδ T cells, a T cell subset possessing a
combination of innate and adaptive immune cell traits
[1]. Activated γδ T cells have strong cytotoxic effector
functions, by means of both death receptor/ligand and
cytolytic granule pathways. Moreover, they have an im-
munoregulatory function, producing various cytokines,
including the T helper (Th)1-associated cytokines tumor
necrosis factor (TNF)-α and interferon (IFN)-γ [1]. γδ T
cells are considered to be important players in cancer
immune surveillance evidenced by; (a) the increased in-
cidence of tumors in γδ T cell deficient mice [2, 3], (b)
the overrepresentation of γδ T cells in reactive lymphatic
regions associated with neoplasia, including acute mye-
loid leukemia (AML) [4], (c) their infiltration into solid
tumors [5], and (d) their potential to kill a variety of
tumor cells [1]. Pointedly, tumor-infiltrating γδ T cells
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recently emerged as the most significant favorable prog-
nostic immune population across 39 malignancies [6].
As γδ T cells can kill tumor cells without previous con-
tact and do not induce graft-versus-host disease, the
adoptive transfer of γδ T cells could be a promising al-
ternative for stem cell transplantation and adoptive
transfer of αβ T cells [7].
Among the various tumor targets of γδ T cells [8], we
focused on AML, a heterogeneous hematological malig-
nancy involving the clonal expansion of myeloid blasts
in the bone marrow and peripheral blood. Although sig-
nificant improvement in treatment of AML has been
made, the unfortunate reality is that currently available
treatments are largely ineffective for most AML patients
[9, 10]. In pursuit of new treatment options, several lines
of evidence suggest that immunotherapy is an active mo-
dality in AML [11]. This includes the graft-versus-
leukemia effect associated with allogeneic hematopoietic
stem cell transplantation (HSCT), where it has been
demonstrated that elevated γδ T cell immune recovery
after HSCT is associated with a better outcome in terms
of infections, graft-versus-host disease and overall sur-
vival [12–14]. Moreover, while the use of HSCT is re-
stricted to a minority of patients due to, among other, its
high transplant-related mortality and morbidity [10, 15],
γδ T cell immune therapy is well-tolerated and safe [7, 16].
Adoptive transfer of γδ T cells is therefore an inter-
esting alternative to tackle minimal residual disease
and the high relapse rate in AML patients, optionally
in combination with HSCT [17] or other (new) thera-
peutic agents [18–20]. Overall, while γδ T cell therapy
holds great promise, clinical results are thus far mod-
est, underscoring the need to further enhance the im-
munogenicity of the γδ T cell product [21].
γδ T cells can be expanded, using combinations of
cytokines and phosphoantigens (e.g., isopentenyl pyro-
phosphate (IPP)) or aminobisphosphonates (e.g., zole-
dronate) [22]. The inclusion of aminobisphosphonates
relies on their inhibition of farnesyl pyrophosphate syn-
thase, a key enzyme of the mevalonate pathway, leading
to accumulation of mevalonate metabolites such as IPP
[23]. When peripheral blood mononuclear cells (PBMC)
are treated with zoledronate, IPP will selectively accu-
mulate in monocytes, due to the efficient drug uptake by
these cells [24]. Therefore, in the absence of monocytes,
addition of aminobisphosphonates is inefficient for in-
duction of γδ T cell expansion, and the use of IPP or re-
lated phosphoantigen is required. To date, the standard
protocol for the expansion of γδ T cells out of PBMC re-
lies on the combination of zoledronate and interleukin
(IL)-2 [25].
Limitations on the use of IL-2, relating to among other
its toxicity, invigorate the investment in exploring other
cytokines of the IL-2 family (also called the common γ
chain cytokine family; IL-4, IL-7, IL-9, IL-15, and IL-21)
[26]. IL-15 is of interest as it is closely related to IL-2
and has got the top position in the US National Cancer
Institute’s ranking of 20 immunotherapeutic drugs with
the greatest potential for broad usage in cancer therapy
[27]. Moreover, both cytokines mediate their effects
through a heterotrimeric receptor complex consisting of
a cytokine specific α-chain (IL-2Rα or IL-15Rα), the IL-
2/15Rβ-chain, and the common γ-chain [28]. IL-2 and
IL-15 share many functions in regulating both adaptive
(stimulation of T cell proliferation and induction of cyto-
toxic T lymphocytes) and innate (activating natural killer
(NK) cells) immune responses [29]. In spite of the re-
semblances between both cytokines, they also have dif-
ferent functions in vivo. IL-15 is specifically known for
its role in the maintenance of long-lasting, high-avidity
T cell responses, whereas IL-2 may induce activation-
induced cell death and provoke maintenance of regula-
tory T cells [26, 30]. Therewithal, IL-15 has shown effi-
cacy in murine models of malignancy, even when IL-2
failed [31, 32]. Clinical trials with IL-15 as monotherapy
have recently been initiated, investigating its therapeutic
potential. When looking at the lymphocyte subsets in
blood, both γδ T cell proliferation and activation were
observed after IL-15 administration.
These results stressed the need for a detailed
characterization of the sheer effect of IL-15 on untouched
and isolated γδ T cells. The latter will be discussed in the
first part of this paper, followed by the translation of the
results into a γδ T cell expansion protocol for adoptive
transfer.
Methods
Ethics statement and cell material
This study was approved by the Ethics Committee of the
Antwerp University Hospital (UZA; Edegem, Belgium)
under the reference number B300201419756. Experiments
were performed using buffy coats derived from healthy
volunteer whole blood donations (supplied by the blood
bank of the Red Cross, Mechelen, Belgium) and blood
samples from patients with AML obtained from the
hematological division of the UZA (Table 1). PBMC were
isolated by Ficoll density gradient centrifugation (Ficoll-
Paque PLUS; GE Healthcare, Diegem, Belgium). Un-
touched γδ T cells were isolated from PBMC using the
EasySep™ Human Gamma/Delta T Cell Isolation Kit
(Grenoble, France), according to the manufacturer’s in-
structions. The purity of the γδ T cells was on average
94 % (min-max; 89–98 %). Isolated γδ T cells (1 × 106
cells/mL) were cultured for 5 days in Iscove’s Modified
Dulbecco’s Medium (IMDM, Life Technologies, Merel-
beke, Belgium), supplemented with 10 % fetal bovine
serum (FBS, Life Technologies), IPP (30 μg/mL; tebu-bio,
Le-Perray-en-Yvelines, France), and IL-2 (100 IU/mL;
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Immunotools, Friesoythe, Germany) or IL-15 (12.5 ng/mL;
Immunotools). The Burkitt’s lymphoma tumor cell line
Daudi was kindly provided to us by the laboratory of Prof.
Kris Thielemans (Free University of Brussels, Brussels,
Belgium), and the multiple myeloma cell line U266 was a
gift from Prof. Wilfred Germeraad (Maastricht University
Medical Center, Maastricht, the Netherlands).
Proliferation assay
To test the ability of IL-2 and IL-15, in combination with
IPP, to induce γδ T cell proliferation, a 5,6-carboxyfluores-
cein diacetate succinimidyl ester (CFSE; Invitrogen, Merel-
beke, Belgium) flow cytometry-based proliferation assay
was performed with isolated γδ T cells. Unstimulated
CFSE-labeled γδ T cells served as negative control. After
5 days, cells were stained with LIVE/DEAD® Fixable Aqua
Stain (Life Technologies), CD56-PE (Becton Dickinson
(BD); Erembodegem, Belgium), CD3-PerCP-Cy5.5 (BD),
and γδ Tcell receptor (TCR)-APC (Miltenyi) and analyzed
using a FACSAria II cytometer (BD). γδ T cell prolifera-
tion was assessed by quantifying the percentage of prolif-
erating (CFSE-diluted) cells within the viable (LIVE/
DEAD−) CD3+γδTCR+ gate.
Expansion protocol of γδ T cells (for adoptive transfer)
PBMC were resuspended in Roswell Park Memorial
Institute (RPMI) supplemented with 10 % heat-
inactivated human AB serum (Invitrogen, Merelbeke,
Belgium), zoledronate (5 μM; Sigma-Aldrich, Die-
gem, Belgium), IL-2 (100 IU/mL), and/or IL-15
(100 IU/mL) at a final concentration of 1 × 106 cells/
mL. Cell cultures were maintained at a cell density
of 0.5–2 × 106 cells/mL and were replenished every 2
to 3 days by adding IL-2/IL-15-supplemented
medium. Phenotypic and functional assays were per-
formed on cells harvested at least 14 days after first
stimulations.
Immunophenotyping
Freshly isolated and 5-day proliferated γδ T cells were
membrane-stained with the following monoclonal anti-
bodies; γδ TCR-FITC (Miltenyi), CD56-PE (BD), CD69-
PE (BD), and HLA-DR-PE (BD). Propidium iodide (PI;
Life Technologies) was added to exclude dead cells from
phenotypic analysis. Data acquisition was performed on
a FACScan multiparametric flow cytometer (BD).
Phenotypic characterization of γδ T cells was examined
pre- and post-expansion, using CD27-FITC (BD), CD69-
FITC (BD), CD56-PE (BD), CD80-PE (BD), CD45RA-
PE-Cy7 (BD), CD28-PerCP-Cy5.5 (BD), CD16-PB (BD),
CD86-V450 (BD), γδ TCR-APC (Miltenyi), and HLA-
DR-APC-H7 (BD). Live/Dead® Fixable Aqua Stain was
used to distinguish viable from non-viable cells. Data
were acquired on a FACSAria II flow cytometer (BD).
Corresponding species- and isotype-matched antibodies
were used as controls.
Cytokine production
γδ T cell cultures were set up as described above. After
5 days of proliferation, cell-free supernatants were har-
vested and stored at −20 °C before analysis. Samples
were assessed by using enzyme-linked immunosorbent
assay (ELISA) for the presence of TGF-β (eBioscience,
Vienna, Austria) and by using electrochemiluminescence
immunoassay (ECLIA; Meso Scale Discovery (MSD),
Rockville, MD, USA) for the presence of IFN-γ, TNF-α,
IL-5, IL-10, and IL-17. Cytokine measurements were also
performed on supernatant of γδ T cell cultures stimulated
for an additional 4 h with the tumor cell lines Daudi and
U266 at an effector-to-target (E:T) ratio of 5:1.
Intracellular staining
After 14 days of γδ T cell expansion, IFN-γ and TNF-α
production was measured using a flow cytometric-based
intracellular staining assay. Measurements were also per-
formed after an additional hour of stimulation with
Table 1 AML patient characteristics
P Sex Age (years) WHO type Disease stage PB blast % BM blast % Molecular Cytogenetics
A f 51 AML-nos R1 6.5 16.2 WT1+ nl
B m 51 AML-rga Dx 50 64.4 NPM1+, WT1+ nl
C m 62 AML-nos Dx 2 72 ASXL1+ Trisomy 8







E f 76 AML-mds Evolution from MDS 18 ND ND ND
F m 52 AML-rga Dx 92.5 94.5 WT1+, NPM1+, FLT3-ITD+ inv(3)(q21q26)
G f 62 AML-nos CR1 0 0.8 ASXL1+ trisomy 8
AML acute myeloid leukemia, P Patient, f female, m male, WHO World Health Organization (WHO) 2008 classification for AML, AML-nos AML not otherwise
specified, AML-rga AML with recurrent genetic abnormalities, AML-mds AML with myelodysplasia (MDS)-related changes, R1 first relapse of AML, Dx diagnosis
stage, CR1 first complete hematological remission of AML, PB blast % percentage of AML blasts in peripheral blood, BM blast % percentage of AML blasts in bone
marrow, ND no data, WT1 overexpression of Wilms’ tumor 1 (WT1) gene transcript, NPM1 presence of mutated nucleophosmin 1 (NPM1), ASXL1 presence of
mutation in additional sex combs 1 (ASXL1) gene, FLT3-ITD presence of internal tandem duplication of fms-like tyrosine kinase 3 (FLT3), nl normal karyotype
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Daudi or U266 cells (E:T ratio = 5:1). Brefeldin A (Golgi-
Plug 1 μL/mL; BD) was added to the different conditions
(1 × 106 cells/mL) and incubated for 3 h at 37 °C/5 %
CO2. γδ T cells were then washed and incubated with
Live/Dead® Fixable Aqua Stain, CD3-PerCP-Cy5.5 (BD)
and γδ TCR-APC (Miltenyi) for 30 min at 4 °C. Subse-
quently, cells were fixed and permeabilized, using the
Foxp3/Transcription Factor Staining Buffer Set
(eBioscience), according to the manufacturer’s instruc-
tions. Intracellular staining antibodies (IFN-γ-FITC and
TNF-α-PE-Cy7, BD) or the corresponding isotype con-
trol were added and allowed to bind for 1 h at 4 °C.
Cytotoxicity assay
A flow cytometry-based lysis assay was performed in
order to determine the killing activity of γδ T cells
against the tumor cell lines Daudi and U266. Tumor
cells were labeled prior to co-culture with PKH67 Green
Fluorescent Cell Linker dye (Sigma-Aldrich), according
to the manufacturer’s protocol, and subsequently co-
cultured with γδ T cells at different E:T ratios (1:10, 1:5,
1:1, 5:1, and 10:1). After 4 h, cells were acquired on a
FACSAria II flow cytometer following staining with
annexin V-APC (BD) and PI. Killing was calculated
based on the percentages of viable (annexin V−/PI−)
cells within the PKH67+ tumor cell population using
the following equation: % killing = 100 − [(% viable
tumor cells with γδ T cells/% viable tumor cells with-
out γδ T cells) × 100].
Statistics
Flow cytometry data were analyzed using FlowJo (v10;
Treestar, Ashland, OR, USA). GraphPad Prism software
(v5.0; San Diego, CA, USA) was used for statistical
calculations and artwork. Shapiro-Wilk normality test was
performed to ascertain the distribution of the data. p
values <0.05 were considered statistically significant. All
data are depicted as means ± standard error of the mean.
Results
Enhanced γδ T cell proliferation in response to IL-15,
concomitant with an activated phenotype
Stimulation of αβ T cell proliferation is a characteristic
of both IL-2 and IL-15. To assess their effect on γδ T
cells, in combination with IPP, a 5-day proliferation assay
was performed using isolated γδ T cells (Fig. 1). Un-
stimulated γδ T cells did not proliferate and were used
as negative control. Although stimulatory effects were
seen to some extent with the combination of IL-2+IPP,
as evidenced by CFSE dilution, no statistical significance
was reached relative to unstimulated γδ T cells. In con-
trast, IL-15+IPP stimulation induced distinct γδ T cell
proliferation (Fig. 1). This finding was confirmed by a
higher absolute number of γδ T cells after 5-day culture
with IL-15+IPP. Calculating mean fold expansion, being
the number of γδ T cells after stimulation divided by the
number of γδ T cells at the start, IL-2+IPP and IL-15
+IPP stimulation resulted in a mean fold expansion of
1.35 ± 0.15 x106 and 2.18 ± 0.31 x106 γδ T cells, respect-
ively. Furthermore, exposure of human peripheral blood
γδ T cells to IL-15+IPP resulted in an improved activated
phenotype. Surface expression of CD69 augmented from
1.63 ± 0.52 % (basal level) to 15.85 ± 3.80 % (IL-2+IPP)
and 26.55 ± 3.83 % (IL-15+IPP), and HLA-DR expression
went up from 12.16 ± 2.36 % (basal level) to 64.58 ± 5.63 %
(IL-2+IPP) and 63.93 ± 7.63 % (IL-15+IPP). Notably,
CD56 expression was significantly higher on IL-15+IPP
stimulated γδ T cells (38.34 ± 4.83 %) than on
Fig. 1 Purified γδ T cell stimulation with IL-15 and IPP for 5 days induces their proliferation. a Isolated γδ T cells were stimulated with IL-2+IPP
(gray bar) or IL-15+IPP (dark bar) for 5 days. Unstimulated γδ T cells (white bar) were used as negative control. The percentage of proliferated
(CFSE-diluted) cells within the viable γδ T cell population was determined by flow cytometry (n = 5) b. Histogram overlays show CFSE dilution
and gating of unstimulated γδ T cells (gray-filled area) and γδ T cells exposed to IL-2+IPP or IL-15+IPP (black line) for one representative donor.
Friedman test with Dunn’s multiple comparison test. **p < 0.01; ns not significant
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unstimulated (19.20 ± 4.49 %) and on IL-2+IPP stimulated
γδ T cells (28.14 ± 4.73 %).
IL-15+IPP stimulated γδ T cells display strong Th1
cytokine responses and are more effective killers than
IL-2+IPP γδ T cells
An important question in the context of cancer im-
munotherapy is whether IL-15, as compared to IL-2, can
boost γδ T cell effector functions, in terms of cytokine
secretion and cytotoxic capacity. γδ T cells stimulated
with either IL-2+IPP or IL-15+IPP are characterized by
a largely pro-inflammatory cytokine profile comprising
IFN-γ and TNF-α. IFN-γ levels were typically >68 ng/
mL/1 × 106 γδ T cells. On average, 3512 ± 2140 and
4506 ± 2527 pg/mL/1 × 106 γδ T cells of TNF-α was de-
tected in supernatant of 5-day cultures of IL-2+IPP and
IL-15+IPP activated γδ T cells, respectively. With the ex-
ception of the IL-5 concentration, for which a 4.4-fold
higher concentration was produced by IL-2+IPP γδ T
cells, no significant difference was found in the non Th1
cytokine secretion (IL-10, IL-17 and TGF-β tested) be-
tween both γδ T cell types. After 5 days, γδ T cell cul-
tures were harvested and exposed to Daudi or U266
tumor cells, to verify their antitumor activity, including
cytokine secretion (Fig. 2a) and cytolytic capacity
(Fig. 2b). The same trends were observed as prior to
tumor cell exposure, i.e., a clear Th1 response for both
IL-2 and IL-15-cultured γδ T cells. However, IL-15+IPP
γδ T cells gave rise to significantly higher concentrations
of IFN-γ compared to IL-2+IPP γδ T cells, whereas the
latter were more prone to a Th2 and Th17 response. As
direct antitumor activity is a hallmark of γδ T cells, and
an important asset for immunotherapy, γδ T cell-
mediated cytotoxicity was tested next against Daudi and
U266 cells. γδ T cell cytotoxicity augmented with in-
creasing E:T ratios and γδ T cells from all donors were
Fig. 2 Distinct Th1 cytokine release and marked tumor cell killing by IL-15+IPP activated γδ T cells. a γδ T cell invigorated for 5 days with IL-15
and IPP (dark bar) or IL-2 and IPP (gray bar) were stimulated for 4 h with U266 cells (E:T = 5:1). Bar graphs represent the cytokine secretion level of
1 million γδ T cells (pg/mL), as determined by ECLIA (IFN-γ, TNF-α, IL-5, IL-10, and IL-17) and ELISA (TGF-β). Data are depicted as mean of duplicate
measurements of six independent donors. Wilcoxon matched-pairs signed rank test. b γδ T cells stimulated for 5 days with IL-15+IPP (filled
squares) or IL-2+IPP (filled circles) were analyzed by flow cytometry for cytotoxicity against the tumor cell lines Daudi and U266. Target cell killing
was determined by annexin V/PI staining after 4-h incubation at different E:T ratios. Results are expressed as mean percentage killing, calculated
using the formula specified in the “Methods” section. Data are from six different experiments involving 6–12 different donors. Paired t test.
**p < 0.01; *p < 0.05
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able to kill both tumor cell lines. In addition, γδ T cell-
mediated lysis was unambiguously stronger for the IL-15
+IPP stimulated γδ T cells in comparison with the IL-2
+IPP stimulated ones against both Daudi and U266
(Fig. 2b).
IL-15 boosts IL-2/zoledronate-mediated expansion
of γδ T cells
As a first step in the clinical translation of the preceding
results towards an improved protocol for the expansion
of γδ T cells for adoptive transfer, expansion based on
stimulation of PBMC with IL-2 and zoledronate was
compared with responsiveness to IL-15 and zoledronate.
Of the four healthy donors tested, only half of the cul-
tures stimulated with IL-15 and zoledronate succeeded.
One culture was considered to have failed due to a cul-
ture viability of less than 50 % and another one due to
the absence of γδ T cell expansion. Yet, IL-2+zoledro-
nate-mediated γδ T cell expansion occurred in all four
donors. On the other hand, when IL-15 was added as a
third stimulus to the standard expansion protocol (IL-
2+zoledronate), a clear effect was detected (Fig. 3).
Despite the fact that the percentage (Fig. 3b) and viability
of γδ T cells after 14 days were similar between cultures
stimulated with IL-2+zoledronate or IL-2+IL-1 zoledro-
nate, a significant increase in total γδ T cell yield was ob-
served when IL-15 was added to the cultures (Fig. 3a). On
average, IL-2+zoledronate cultures showed a 590-fold in-
crease in γδ T cells after 14 days, whereas addition of IL-
15 almost led to a 1000-fold increase. To ascertain the
strength of the immune proliferative and stimulatory ef-
fect of IL-15, immune cells of AML patients (Table 1)
were included. First, AML patients had a significantly
lower proportion of γδ T cells in PBMC in comparison
with healthy donors (0.30 ± 0.13 versus 1.91 ± 0.37 %, re-
spectively; p = 0.0234). Next, it should be noted that in
contrast to the 100 % success rate of γδ T cell expansion
(defined as ≥70 % γδ T cells after culture [33, 34]) starting
from PBMC of healthy donors, less than half of the γδ T
cell expansion cultures from AML patients succeeded
Fig. 3 Kinetics of γδ T cell expansion. a The graph represents the average (n = 6, healthy donors) mean fold total number of γδ T cells, calculated
as the absolute number of γδ T cells at the respective time point divided by the absolute number of γδ T cells at start of the expansion culture.
b Bar graphs showing the proportion of γδ T cells at various times during the culture, starting from day 0. Cultures expanded with zoledronate
and IL-2 are displayed as gray bars, and cultures supplemented with zoledronate, IL-2, and IL-15 are shown as hatched bars. Data are expressed as
mean percentages of 6 healthy donors from three experiments. c The increase in number of “successfully” cultured γδ T cells from different AML
patients is presented as mean fold total number of viable γδ T cells. Patients in remission are indicated by a lowercase r after their letter of identification
(right panel). Wilcoxon matched-pairs signed rank test. P patient; *p < 0.05; ns not significant
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(Table 2). However, no direct correlation could be made
between γδ T cell percentages in PBMC at start and the
success of the expansion culture. Cultures that expanded
relatively poorly, but in which nonetheless sufficient
(viable) γδ T cells were induced for (functional) testing,
were also included. Importantly, similar to the healthy
donors, γδ T cells expansion was convincingly stronger for
all AML patients when IL-15 was added to the cultures
(Fig. 3c).
Fourteen-day expansion using IL-2+IL-15+zoledronate
gives rise to γδ T cells with an activated memory
phenotype
At culture initiation (day 0) and termination (day 14–
15), we subjected the γδ T cell cultures to immunophe-
notyping. Whereas the four distinct effector/memory
states were nearly evenly represented in terms of per-
centages by circulating γδ T cells of healthy donors at
day 0, with a small preponderance for the naïve and cen-
tral memory phenotype, the vast majority of expanded
cells were effector memory γδ T cells and to a lesser
extent central memory γδ T cells (Fig. 4). γδ T cells of
AML patients, however, deviated from this pattern
(Fig. 4). Likely, the stage of the disease, i.e., diagnosis, re-
lapse or remission, plays a role in this phenomenon. For
example, notwithstanding the rather small patient group,
patients at diagnosis or in relapse displayed at day 0 a
higher amount of central memory γδ T cells as com-
pared to healthy donors, whereas remission patients
strikingly had less central memory γδ T cells. Undoubt-
edly, patient-dependent factors also play a role, for in-
stance when looking at the distribution of patient G
(Fig. 4). Still, in analogy with healthy donors, expanded
γδ T cells of AML patients show a clear predominance
for the memory stages (Fig. 4). Further phenotypic
characterization revealed a marked increase in expres-
sion level of the activation associated markers CD56,
CD69 and HLA-DR on expanded γδ T cells of healthy
donors, in combination with an increase in the co-
stimulatory molecules CD80 and CD86 (Fig. 5). Expan-
sion, however, had no effect on the expression of CD16
and CD28. If we then looked at the phenotype of
patient-derived γδ T cells after expansion, we perceive
an increase in the early and late activation markers
CD69 and HLA-DR as well (Fig. 5). Interestingly, γδ T
cells of patients in remission express less HLA-DR (and
CD69) after expansion in comparison to healthy controls
and patients with acute disease. The activated phenotype
of γδ T cells from remission patients is nonetheless
clearly improved upon addition of IL-15. With regard to
CD56 expression, all patient γδ T cells exhibited already
elevated levels at start, similar to those of healthy donors
after expansion. After expansion, a down-regulation of
CD56 is seen, which is more pronounced in patients in
remission and γδ T cells expanded with IL-2+zoledro-
nate. The same phenomenon holds true for CD16 upon
expansion. Concerning the expression of CD80, a
marked upregulation was detected after expansion, even
more pronounced as compared to healthy donors.
Whereas the expression of CD86 is similar for patient A,
patient C, and healthy donors, γδ T cells of patients in
remission expressed less of this co-stimulator after ex-
pansion (Fig. 5). In summary, expanded γδ T cells dis-
play an activated memory phenotype, based on the
enhanced expression of CD69, HLA-DR, CD56, CD80,
and CD86.
The frequency of IFN-γ-producing γδ T cells is consider-
ably higher after IL-2+IL-15+zoledronate expansion com-
pared to IL-15-free expansion
To study the functionality of the expanded γδ T cells, we
first determined their Th1 polarization. In the absence
of additional stimuli, the mean frequency of IFN-γ-
producing γδ T cells after expansion was significantly
higher when stimulated with IL-2+IL-15+zoledronate
(3.28 ± 0.81 %), as compared to IL-2+zoledronate (1.49
± 0.43 %) (Fig. 6a). This more pronounced Th1 profile of
γδ T cells, seen when IL-15 is present during expansion,
also holds true upon addition of tumor cells to the cul-
tures. When Daudi cells were added, we even observed
an amplified IFN-γ production as compared to the con-
trol (no tumor cells) condition (Fig. 6a). Despite having
low numbers of TNF-α-producing γδ T cells, generally
below 1 %, the same trends were seen as with IFN-γ.
Proceeding with immune cells of AML patients, differ-
ent observations were seen as compared to expanded γδ
T cells of healthy donors (Fig. 6b). Whereas the fraction
of γδ T cells positive for IFN-γ after stimulation with IL-
2+IL-15+zoledronate was comparable between healthy
donors and AML patients, IL-2+zoledronate stimulation
gave rise to more IFN-γ positive γδ T cells when derived
from AML patients relative to healthy donors. Moreover,
the IL-2+zoledronate cultures of AML patients
Table 2 Outcome of in vitro expansion of γδ T cells from PBMC
of AML patients
P % γδ T cells IL-2+
zoledronate
% γδ T cells IL-2+
IL-15+zoledronate
Success
A 75.9 91.9 Yes
B 16.8 12.4 No
C 84.4 94.0 Yes
D 17.2 46.6 No
Dr 76.6 89.4 Yes
E 5.65 1.80 No
F 4.31 1.84 No
Gr 27.1 50.8 No
P patient, Pr patient in remission
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performed equally well in terms of IFN-γ production, if
not better, than the IL-2+IL-15+zoledronate condition.
Next, when tumor cells were added to expanded γδ T
cells from patients, blunting of the γδ T cell helper func-
tion could be observed to a certain degree pertaining to
healthy donor expanded γδ T cells. Here, γδ T cells of
patients with active disease did similar in terms of per-
centage IFN-γ positive cells after expansion with or
without IL-15. On the other hand, γδ T cells of remis-
sion patient Dr, of which both protocols had yielded suf-
ficient γδ T cells for functional testing, exhibited an
almost doubling in the number of IFN-γ positive cells
when expanded in the presence of IL-15 and challenged
with tumor cells.
Addition of IL-15 to the expansion medium results in a
significant increase in the γδ T cell-mediated cytotoxicity
against tumor cells
Finally, we determined the cytotoxic potential of the ex-
panded γδ T cells against the Daudi and U266 tumor cell
lines (Fig. 6c). γδ T cells of healthy donors displayed an
increase in tumor cell killing upon increasing E:T ratios.
Notably, addition of IL-15 in the expansion cultures
evoked a superior cytotoxic capacity of expanded γδ T
cells at the 10:1 ratio for both tumor cell lines. Similarly,
the cytotoxic capacity of γδ T cells originating from
AML patients was improved upon expansion in IL-15.
However, in general, killing values of AML-derived γδ T
cells were lower than those of healthy donor γδ T cells.
At the 10:1 ratio, average killing of Daudi by expanded
γδ T cells was 27.26 ± 10.86 and 32.03 ± 14.17 %, with re-
spectively the IL-2+zoledronate (n = 3) and IL-2+15
+zoledronate (n = 5) expansion protocols. For U266 kill-
ing, percentages of 24.89 ± 3.51 and 35.19 ± 4.96 % were
true. Finally, for some AML patients e.g., patient A,
cytotoxic capacity is highly dependent on the target cell
line (Fig. 6c).
Discussion
To date, adoptive immunotherapy using T lymphocytes
has been applied for nearly 30 years [35]. Since then,
vast improvements, including the use of chimeric anti-
gen receptor (CAR) or T cell receptor (TCR) gene-
modified killer T cells, have been made. This resulting in
proven clinical benefit for end-stage cancer patients for
which standard therapy failed and the provision of long-
term protection in some cases [36–38]. Notwithstanding
this progress in the field, one of the major problems en-
countered with the adoptive transfer of classical αβ T
cells, gene-modified or not, is the occurrence of off- and
on-target toxicity [37]. Here, γδ T cells have received re-
cent attention as an alternative cell source for T cell-
mediated anticancer therapy [7]. Namely, both adoptive
transfer and in vivo activation/expansion of γδ T cells
are safe therapeutic modalities that can result in object-
ive clinical responses in the treatment of cancer [7, 16].
A major advantage with using γδ T cells is that they are
unlikely to cause graft-versus-host disease, allowing
them to be generated from healthy donors and given in an
allogeneic setting as an “off-the-shelf” therapeutic [7, 14].
In this study, we explored the beneficial effect of IL-15 on
γδ T cells and its use as stimulatory signal in the ex vivo
expansion of γδ T cells for adoptive transfer. The strength
Fig. 4 Effector memory phenotype of γδ T cells pre- and post-expansion. Average percentage of naïve (CD45RA+CD27+), effector memory
(CD45RA−CD27−), central memory (CD45RA−CD27+) and terminally differentiated (CD45RA+CD27−) γδ T cells, before (unstimulated) and after
expansion, represented as pie charts for six healthy donors. Values of γδ T cells of patients are listed in the table below. - no value due to low cell
number, Pr patient in remission, unst. unstimulated, zol zoledronate
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of IL-15-mediated activation was further validated in γδ T
cells originating from AML patients.
A recent study in rhesus macaques showed that con-
tinuous administration of IL-15 is, among other, associ-
ated with increased numbers of circulating γδ T cells
[39]. This has now been confirmed in the first-in-human
trial of recombinant IL-15, whereby IL-15 administration
in cancer patients induced both γδ T cell proliferation
and activation [26]. These in vivo findings corroborate
with our in vitro results, showing substantial proliferation
of isolated γδ T cells upon stimulation with IL-15+IPP,
but not with IL-2+IPP. In line herewith, Viey et al. dem-
onstrated γδ T cell expansion out of tumor-infiltrating
lymphocytes of renal cell carcinoma patients with bro-
mohydrin pyrophosphate, a synthetic phosphoantigen,
in combination with IL-15, while the combination with
IL-2 was inefficient [5]. However, when we sought to
extrapolate these results into a clinical 2-week expan-
sion protocol based on IL-15 and zoledronate, inconsist-
encies in expansion successes were detected. In our
hands, the best results were obtained when IL-15 and
IL-2 were combined, suggesting that these cytokines
have distinct roles in γδ T cell biology. An advantage of
IL-15 during expansion could be that IL-15 mediates
homeostatic competition between αβ T cells, NK cells
and γδ T cells by a yet unknown indirect mechanism
[40, 41]. While we detect no difference in the final per-
centage of γδ T cells in expansion cultures of healthy
donors with or without IL-15, this is certainly the case
with the cultures of AML patients. In the IL-2+zoledro-
nate cultures, we observed a higher proportion of other
blood mononuclear cells, of which the vast majority
were αβ T cells. Addition of IL-15 may therefore have
counteracted the growth of other cell types such as αβ
Fig. 5 γδ T cell phenotype prior and subsequent to expansion. Comparison of the expression of CD69, HLA-DR, CD56, CD16, CD28, CD80, and
CD86 on unstimulated (white bars), IL-2+zoledronate expanded (gray bars) and IL2+IL-15+zoledronate expanded (hatched bars) γδ T cells. Results
are shown for six healthy donors on the uppermost row as mean percentage. Expression levels of the respective markers of patient γδ T cells are
showed below. Due to the low number of γδ T cells after expansion with IL-2 + zoledronaat of patient D, no data are available. Friedman test with
Dunn’s multiple comparison test. **p < 0.01; *p < 0.05
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T cells, constraining the growth of the γδ T cells, pre-
venting cluster formation and subsequently successful
γδ T cell expansion [40, 41]. It is possible that this
process is more important when there is only a low per-
centage of γδ T cells in the starting material or when γδ
T cells are less responsive, which is often the case in a
malignant setting [42]. Moreover, γδ T cells of AML pa-
tients generally exhibited a higher viability after expan-
sion with IL-15, which was not observed with healthy
donors. The question remains whether this improved
viability is a result or the cause of the enhanced degree
of γδ T cell expansion. Nevertheless, it has been shown
that IL-15 is very competent in supporting survival of
activated γδ T cells, superior to IL-2 [43], and T cell sur-
vival in general [44]. This does not mean that IL-2 is by
definition redundant, as evidenced by our expansion re-
sults. The synergism between IL-2 and IL-15 could lie
in the fact that γδ T cells, in response to zoledronate
and IL-2, upregulate their expression of inter alia IL-
2Rβ and γc [43].
With regard to the effector/memory state of the γδ T
cells after expansion, our results correspond with the
available literature concerning γδ T cells expanded with
IL-2 and zoledronate [25, 45]. In particular, the majority
of expanded γδ T cells from healthy donors and patients
showed for both expansion protocols a predominant ef-
fector memory type and, to a lesser extent, a central
memory phenotype. Hence, the addition of IL-15 had no
apparent influence on the effector/memory state. This is
encouraging, since increased effector memory γδ T cells
are reported to correlate with objective clinical outcomes
in patients treated with zoledronate and IL-2 [46]. On
the other hand, adoptive transfer with αβ T cells has
shown that it may also be important to preserve some
less differentiated T cell subsets within the infused T cell
product, to ensure T cell expansion and potentially long-
Fig. 6 Pro-inflammatory and cytolytic γδ T cell capacity after expansion. Percentage IFN-γ-positive γδ T cells after expansion (no extra stimulus)
and after an additional 4-h stimulation with Daudi or U266 cells (E:T ratio = 5:1) measured by flow cytometry for a six healthy donors and b five
AML patients. c Expanded γδ T cells, with IL2+zoledronate (IL-2+zol) or IL-2+IL-15+zoledronate (IL-2+IL-15+zol), were analyzed by flow cytometry
for cytotoxicity against Daudi and U266. Target cell killing was determined by annexin V/PI staining after 4-h incubation at different E:T ratios. Bar
graphs (white) represent the mean percentage killing of six healthy donors in three independent experiments. The dots display the proportion of
tumor cell killing by γδ T cells of the different patients. Wilcoxon matched-pairs signed rank test. - no value due to low cell number; *p < 0.05
Van Acker et al. Journal of Hematology & Oncology  (2016) 9:101 Page 10 of 13
term T cell persistence [47–49]. Given the presence of
γδ T cells with a central memory phenotype upon expan-
sion, our culture protocol fulfills the above-mentioned ne-
cessity. Moreover, contributing to the rationale of
implementing IL-15 in expansion protocols, it has recently
been shown that IL-15 instructs the generation of human
memory stem T cells, a T cell subset with superior antitu-
mor responses [50], from naive precursors [49, 51].
When looking in detail at the phenotype of cultured
γδ T cells, two findings stand out from our results. First,
incubation with IL-15+IPP led to a significant upregula-
tion of CD56 relative to IL-2+IPP stimulated and un-
stimulated γδ T cells. In addition to the stringent
association of CD56 with NK cells, CD56 has also been
detected on other lymphoid cells, including γδ T cells
and activated CD8+ T cells [52–55]. Moreover, CD56 in
the human hematopoietic system is not restricted to
lymphoid cells. Both CD56+ plasmacytoid dendritic cells
(DCs) and myeloid DCs, including our IL-15 DCs, fea-
ture cytotoxic activity, in addition to serving classical
DC functions [56]. In this context, it has been presumed
that CD56 is associated with activated/cytotoxic effector
immune cells [52, 54, 57–59]. This would implicate that
IL-15 stimulation raises stronger cytotoxic γδ T cells, as
effectively confirmed by the enhanced killing of tumor
cells in our experiments. Moreover, CD56 expression on
γδ T cells following expansion was enhanced as well.
Secondly, upon expansion, an increased expression of
the co-stimulatory molecules CD80 and CD86 was ob-
served. It has been shown that activated γδ T cells are
able to acquire a professional antigen-presenting cell
function, expressing high levels of co-stimulatory mole-
cules [60]. This function may further boost the gener-
ation of a potent and long-lasting immune response.
In view of the functionality of γδ T cells, our experi-
ments clearly show that IL-15, in comparison with IL-2,
has a superior Th1 polarizing effect on γδ T cells and
markedly strengthens the γδ T cell cytotoxic capacity.
These results are supported by in vivo data where intes-
tinal γδ T cells of IL-15−/− knockout mice only produced
small amounts of IFN-γ upon stimulation and showed
significantly lower cytotoxicity against target cells as
compared to wild-type mice [61]. This indicates that IL-
15-mediated signals are indeed indispensable for the de-
velopment of potent antitumor functions. Furthermore,
IL-15 has proved itself superior at maintaining effector
functions of already expanded and activated γδ T cells,
evidenced by a higher IFN-γ production and CD107a ex-
pression after stimulation with zoledronate pre-treated
Daudi cells [43]. In addition, within the context of neo-
natal immunity, it has been shown that expansion of
cord blood γδ T cells with alendronate and IL-15 gave
rise to γδ T cells capable of strong protective immune
responses [62]. Although the differences between the
effects of IL-2 and IL-15 were subtle, higher expression
of among other granzyme B and perforin was detected
after activation with IL-15 [62]. All these data therefore
point towards the fact that IL-15 is a pivotal signal to
generate more powerful effector γδ T cells. This has re-
cently been substantiated by Ribot et al., identifying the
MAPK/ERK-mediated IL-2/IL-15 signaling as the major
functional differentiation pathway of human γδ T cells
towards antitumor (cytotoxic type 1) effector cells [63].
Conclusions
Taken together, we have demonstrated that the addition
of immunostimulatory cytokine IL-15 to in vitro γδ T
cell cultures, derived from both AML patients and
healthy blood donors, resulted in a more activated
phenotype and significantly increased the antitumor
functions of γδ T cells. This was manifested in a higher
yield of expanded γδ T cells, a more pronounced Th1
polarization and an increased cytotoxic capacity, all de-
sirable characteristics for their further use in adoptive
immunotherapy. Therefore, our results strengthen the
rationale to explore the use of IL-15 in clinical adoptive
therapy protocols.
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